Advertisement
Advertisement
September 7, 2015
QT Vascular's Chocolate Touch DCB Cleared in Europe
September 7, 2015—QT Vascular Ltd. announced that it has received European CE Mark clearance for its Chocolate Touch peripheral drug-coated balloon (DCB). The company expects to commence the commercial launch of Chocolate Touch in countries that recognize the CE Mark later this year.
California-based TriReme Medical LLC, which is a subsidiary of QT Vascular, is the developer and manufacturer of the Chocolate Touch device. QT Vascular is based in Singapore.
In QT Vascular’s announcement, Prof. Thomas Zeller, MD, of the Heart Center in Bad Krozingen, Germany, commented, “Chocolate Touch combines the low-trauma Chocolate platform with the proven drug paclitaxel. In my personal experience, the Chocolate Touch has produced excellent acute clinical outcomes. I look forward to presenting the first ENDURE results at the meeting of the German Society of Angiology conference in late September.”
Prof. Zeller is Principal Investigator of the ENDURE study, which is the first-in-human evaluation of the Chocolate Touch DCB for percutaneous transluminal revascularization of infrainguinal arterial disease. In September 2014, the company announced commencement of European enrollment in the ENDURE trial.
Advertisement
Advertisement
